(Presseportal openBroadcast) - Epigenetics Market: Epigenetics is a study of heritable changes in gene expression which involves the change in phenotype without changing genotype, which in turn affects the reading of genes by cells. Epigenetic changes are natural and regular processes but also influenced by various factors like lifestyle, environment, age and state of disease. Epigenetic modifications can manifest a common manner of cells which differentiate terminally to end up as liver cells, skin cells, brain cells etc. Epigenetic change may have more damaging effects which can lead to diseases like cancer. Systems like histone modification, non-coding RNA-associated gene silencing and DNA methylation are considered for initiation of epigenetic change sustainably.

Market Outline: Global Epigenetics Market

The surge in the prevalence of cancer, improving funds and aids for the R&D activities, rise in the partnerships between pharmaceutical and biotechnology companies and research institutes, increase in epigenetics application in non-oncology diseases will propel the epigenetics. Moreover, improved advancements in epigenetics technology, untapped potential of emerging markets like India and China are expected to offer many opportunities for the growth of epigenetics market. However, high instrument cost and the dearth of skilled personnel are expected to hamper the growth of the epigenetics market.

Epigenetics has triggered R&D for new drugs for various cancers, chronic and autoimmune disorders. For example, U.S.FDA approved ramucirumab/Cyramza by Eli Lilly for use in combination with folfiri to treat metastatic colorectal cancer and Novartis’s Farydak and Celgene’s Istodax received FDA approval in 2015. Introduction of advanced technologies and potential investments on R&D activities are expected to fuel the growth of epigenetics. Currently, companies are focussing on detection of DNA methylation patterns and histone modification. For example, Epigenomic’s EPI ProColon 1.0, Quest Diagnostic’s ColoVantage, Abbott’s Real Time mS9 are few tests which detect SepT9 DNA methylation biomarker for colorectal carcinoma.

Geographically Epigenetics Market is segmented as Latin America, Europe, Asia- Pacific, North America, The Middle East & Africa. North America is expected to account for largest market share in regional market of epigenetics due to rise in prevalence of cancer, high funding on R&D, increasing acquisitions and collaborations along large pharma companies, high adaptation and awareness of new technologies and healthcare infrastructure.